Therapeutic interventions and oxidative stress in diabetes
- 1 January 2009
- journal article
- review article
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. ume (14), 192-209
- https://doi.org/10.2741/3240
Abstract
Many therapeutic agents that are used in patients with diabetes mitigate oxidative stress. These agents are of particular interest because oxidative stress is elevated in diabetes and is thought to contribute to vascular dysfunction. Agents that merely quench already formed reactive oxygen species have demonstrated limited success in improving cardiovascular outcomes. Thus, although vitamin E, C, and alpha lipoic acid appeared promising in animal models and initial human studies, subsequent larger trials have failed to demonstrate improvement in cardiovascular outcomes. Drugs that limit the production of oxidative stress are more successful in improving vascular outcomes in patients with diabetes. Thus, although statins, ACE inhibitors, ARBs and thiazolinediones are used for varied clinical purposes, their increased efficacy in improving cardiovascular outcomes is likely related to their success in reducing the production of reactive oxygen species at an earlier part of the cascade, thereby more effectively decreasing the oxidative stress burden. In particular, statins and ACE inhibitors/ ARBs appear the most successful at reducing oxidative stress and vascular disease and have potential for synergistic effects.Keywords
This publication has 99 references indexed in Scilit:
- Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes modelJournal of the American College of Cardiology, 2004
- Interleukin-6 Induces Oxidative Stress and Endothelial Dysfunction by Overexpression of the Angiotensin II Type 1 ReceptorCirculation Research, 2004
- Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-γ Agonist in HypercholesterolemiaCirculation, 2003
- HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen SpeciesHypertension, 2001
- Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II)Free Radical Research, 1999
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.JCI Insight, 1998
- UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 DiabetesDiabetes Care, 1998
- Effects of Treatment With the Antioxidant α-Lipoic Acid on Cardiac Autonomic Neuropathy in NIDDM Patients: A 4-month randomized controlled multicenter trial (DEKAN Study)Diabetes Care, 1997
- Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trialThe American Journal of Cardiology, 1995